PharmaSource Podcast

Life Science Networks
  • 0.0 (0)
  • 生命科學
  • 每星期更新

Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing. In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides. Make sure to subscribe for your regular dose of pharma insight.

  1. How Biotechs Can De-Risk External Manufacturing, Navigate Geopolitical Challenges, and Plan for Capacity Constraints – Dr. Reza Oliyai

    3日前

    How Biotechs Can De-Risk External Manufacturing, Navigate Geopolitical Challenges, and Plan for Capacity Constraints – Dr. Reza Oliyai

    “Intrinsically, there is nothing wrong with using Chinese CDMOs. But because of geopolitical issues, some large pharma want to have redundancy of that supply chain in the US.” Dr. Reza Oliyai, President and CEO of Oliyai Consulting Corporation, spent 28 years at Gilead Sciences rising from research scientist to SVP overseeing 1,700 people across seven sites and multiple modalities including biologics, ADCs, small molecules, and sterile manufacturing. In this PharmaSource podcast episode, Reza shares his framework for helping biotechs de-risk their external manufacturing strategy, navigate geopolitical supply chain challenges, and make phase-appropriate decisions that balance speed with resource constraints. Read the full article

    34 分鐘
  2. Digital Transparency Platform to be Launched by SGS CDMO Solutions

    4日前

    Digital Transparency Platform to be Launched by SGS CDMO Solutions

    By 2028, SGS CDMO Solutions’ MHRA and FDA-inspected site in Wales will operate entirely without paper. For biotech and Pharmaceutical sponsors, this provides a better way to run development and manufacturing projects. “If it can’t be done digitally, then we don’t want to do it,” says Paul Broomhead, Head of Site. The result is a digitally native CDMO where data, processes, and decisions live in one. Paul Broomhead, Head of Site at SGS CDMO Solutions in Wales, is leading an ambitious digital transformation. In this exclusive interview, Paul reveals why SGS is making a commitment to digital infrastructure, how the transformation creates competitive advantages for biotech sponsors, and what “digitally native” manufacturing actually means in practice for pharmaceutical development and commercialization. Read more

    27 分鐘
  3. 2026 US Pharma Outsourcing: Gil Roth on FDA Cuts, Pricing Pressures and CDMO Strategy

    2月1日

    2026 US Pharma Outsourcing: Gil Roth on FDA Cuts, Pricing Pressures and CDMO Strategy

    FDA hemorrhaging staff while promising to fast-track advanced modalities. BIOSECURE Act signed into law with five-year phase-out timelines. Tariffs creating 50% cost increases on manufacturing equipment. Most Favored Nation deals cutting prices. Cell and gene therapy facilities closing despite scientific promise. Welcome to 2026 pharma manufacturing. In the latest episode of the PharmaSource podcast, Gil Roth, President of the Pharma and Biopharma Outsourcing Association (PBOA), explains how pharma companies are impacted by policy changes, and how CDMOs are building flexibility into capital planning, manufacturing infrastructure, and customer contracts to survive chaos that makes forecasting impossible.Gil Roth is speaking at CDMO Live Europe and CDMO Live Americas

    34 分鐘
  4. Reshoring Pressure vs. Manufacturing Reality: Report from ExM Leader Boston

    1月26日

    Reshoring Pressure vs. Manufacturing Reality: Report from ExM Leader Boston

    Fresh from External Manufacturing Leaders in snowy Boston, in this episode we are sharing insights from senior biopharma executives confronting an impossible challenge: how do you reshore when there's nowhere to reshore to? Highlights of the event include why biotechs built on Chinese manufacturing economics are scrambling, why US capacity for ADCs and sterile fill-finish is completely tied up, and how manual operations are threatening American competitiveness. Plus: the 2026 strategies leaders are actually implementing, from AI-powered Digital Twins to creative redundancy plays. Thanks to Aenova Group for co-hosting ExM Leader Boston with us. Download the full report here: https://pharmasource.global/content/resources/exm-leaders-boston-26/

    9 分鐘
  5. Why Radiopharma Must Compete on Service Excellence – Not Clinical Data

    1月18日

    Why Radiopharma Must Compete on Service Excellence – Not Clinical Data

    “There are 437 active clinical trials in radiopharmaceuticals, and 100 companies developing them. If your logistics are not better, there is no other differentiator. You need to compete by experience.” When Kostja Paschalidis and his co-founders left their roles developing one of the leading radiopharmaceutical products, they recognised a fundamental shift in pharmaceutical manufacturing. Unlike traditional drugs where marketing drives commercial success, radiopharmaceuticals demand something entirely different: flawless service delivery. As co-founder and head of systems and logistics at Firm, a design consultancy specialising in radiopharmaceutical services, Kostja has identified why operational excellence—not clinical superiority—will determine market winners. In the latest PharmaSource podcast episode, he explains why radiopharmaceutical companies must become service-centric organisations to succeed and how a lack of standardisation and suitable technology creates barriers to scale.

    33 分鐘
  6. Supply Chain Resilience Through Geographic Redundancy [Simtra BioPharma Solutions CEO]

    1月12日

    Supply Chain Resilience Through Geographic Redundancy [Simtra BioPharma Solutions CEO]

    “We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.” Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from Baxter International (Baxter) in October 2023. Franco has led over $500 million in capital investments to double capacity and create mirrored capabilities across sites in Indiana, US, and Halle/Westfalen, Germany. Franco brings industry experience from Procter & Gamble, Johnson & Johnson, Novartis, and Patheon, which became part of Thermo Fisher Scientific, where he helped shape integrated CDMO strategies. In this PharmaSource podcast, recorded at CPHI 2025, Franco explains how Simtra is navigating supply chain challenges, tariff uncertainties, and injectable manufacturing complexity, from GLP-1s to antibody drug conjugates. Read more.

    24 分鐘
  7. How Integrated Drug Development and Manufacturing Creates Speed Advantage in Contract Pharma

    1月5日

    How Integrated Drug Development and Manufacturing Creates Speed Advantage in Contract Pharma

    “Process chemistry alone is no longer the whole story—it needs to be connected with engineering solutions, digital tools, and data utilization.” Stefan Randl, Chief Scientific Officer at Siegfried, joined the Swiss-based CDMO in January 2025 after 16 years at Evonik, where he led innovation management for healthcare, ran drug substance operations in the US, and headed sales across Asia. Read more.

    34 分鐘
  8. How Charles River Helps Sponsors Accelerate Drug Development Through Strategic Testing

    29/12/2025

    How Charles River Helps Sponsors Accelerate Drug Development Through Strategic Testing

    “Biotechs need flexibility and have limited budgets, while big pharma looks for long-term partnerships, reliability, scalability, and new technologies.” Luis Berrade, Senior Director of Global Biologics Testing Sales at Charles River Laboratories, has spent his career helping pharmaceutical and biotech companies bring therapies to market faster and safer. With a PhD in medicinal chemistry and experience spanning both contract manufacturing and testing services, Luis now leads Charles River’s global biologics testing commercial strategy, working with companies of all sizes to navigate the complex regulatory landscape. In an episode of the PharmaSource podcast, Luis shares his insights on when sponsors should start thinking about testing strategy, common mistakes that create bottlenecks, and how emerging technologies like next-generation sequencing are reshaping the biologics testing landscape. Read more.

    18 分鐘
查看全部 (210)

關於

Welcome to the PharmaSource podcast: the pharma and biotech podcast that explores the latest trends, challenges, and commercial opportunities shaping the biopharma manufacturing and outsourcing. In each episode we'll be speaking with top executives, researchers, and outsourcing experts, who share their perspectives on topics such as building a smarter, more sustainable supply chain, how to partner with CDMOs, digital transformation, procurement and external manufacturing strategies, and plenty more besides. Make sure to subscribe for your regular dose of pharma insight.

資料

  • 創作者
    Life Science Networks
  • 活躍年份
    2023年 - 2026年
  • 單集
    210
  • 分級
    兒童適宜
  • 版權
    © Life Science Networks
  • 節目網站
    PharmaSource Podcast